No one is optimistic that Congress will make changes in benefits or outlays needed to improve the financial picture.
WASHINGTON-The financial health of the Medicare program continues to deteriorate, according to the annual Medicare Trustees report. No one is optimistic that Congress will make changes in benefits or outlays needed to improve the financial picture.
The report forecasts that Medicare's hospital fund will start running out of money in 2024. The time frame has held steady only because last year's deficit-reduction legislation calls for 2% cuts in program spending-a policy that is unlikely to stand. Instead, both short-term and long-term Medicare spending will rise higher than previously predicted.
The solution, according to the Obama administration, lies in implementing the Patient Protection and Affordable Care Act (PPACA). An analysis from the White House says that the reform legislation will save more than $200 billion in Medicare spending through 2016. Savings would come from ending extra payments to Medicare Advantage plans, cracking down on fraud and abuse, and shifting reimbursement to pay providers based on quality performance.
Last month, the Centers for Medicare and Medicaid Services (CMS) announced that 27 provider groups will participate in the Medicare Shared Savings program. It still remains far short of predictions that up to 270 ACOs would participate. CMS now is reviewing more than 150 additional ACO applications.
Bonuses also will depend on how well an ACO performs on 33 quality measures across four domains. Data from earlier demonstration projects indicate, however, that ACOs might do better in meeting quality standards than in generating savings.
Although Medicare is supposed to save billions by cutting rates to Medicare Advantage, CMS is giving MA plans more time to achieve star quality ratings that carry hefty bonuses and rebates. CMS is permitting the vast number of three-star plans to enjoy the bonuses through a large demonstration project.
Now the Government Accountability Office (GAO) and Republican critics are blasting that decision as likely to cost $8.35 billion over 10 years. And the demonstration program is so broad that it's unlikely to yield a valid assessment.
In an analysis prepared for Sen. Orrin Hatch (R-Utah), GAO urges CMS to cancel the star-rating bonus demonstration. Hatch charges CMS with abusing its authority and using the demonstration program for political purposes. The aim, he says, was to "divert attention away from cuts to the popular Medicare Advantage program."
Hatch, who faces a tough re-election campaign, raised questions about the legality of a demonstration program that costs billions of dollars and is unlikely to assess whether a scaled bonus structure spurs quality improvement.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More